Events & Presentations

Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021.

The presentation will be available for on-demand listening beginning March 9, 2021 at 7:00 am (EST) and archived for 90 days.

Webcast link:   https://journey.ct.events/view/13f2dc13-e58d-46ec-aba7-9bf66a19982e

Webcast to begin at approximately 9 a.m. ET on Thursday, December 14, 2017

The webcast may be accessed directly via the following link:
https://dentons.adobeconnect.com/galt_board/

Type your full name in the blank field to "Enter as a Guest" and click the "Enter Room" button.

The presentation may also be heard via teleconference by dialing 866.225.1342 (within the United States).

A list of international dial-in numbers can be found here.

The passcode for participants is 2856445641.

Please dial-in or log-in approximately 10 minutes before the event begins to ensure a timely connection.

Galectin Therapeutics 2016 Annual Meeting of Stockholders - Corporate Update

Webcast to begin at approximately 1:30 p.m. ET on Thursday, December 15, 2016

The webcast may be accessed directly via the following link:  https://dentons.adobeconnect.com/galt_board/

The presentation may also be heard via teleconference by dialing 866-225-1342 (within the United States).

A list of international dial-in numbers can be found here:  https://www.tcconline.com/listNumbersByCode.action?confCode=8620018752

The passcode for participants is 8620018752

Please log in approximately 10 minutes before the event to ensure a timely connection.

Participant dial-in number: 1-888-317-6003
Pin number: 4681161
Webcast link:  http://services.choruscall.com/links/galt160927.html

Galectin Therapeutics (Nasdaq:GALT) hosted a corporate update webcast on Thursday, May 21, 2015, immediately following the business portion of the Company’s Annual Meeting of Stockholders. Peter Traber, M.D., president, chief executive officer and chief medical officer discussed the company’s pipeline of galectin inhibitor compounds and progress in development of treatments for liver fibrosis and cancer. View the video replay: http://galectintherapeutics.com/stockholder-meeting-webcast/

Galectin Therapeutics (NASDAQ: GALT) held a webcast to provide an update following the Company's Annual Meeting of Shareholders. To view a PDF of the document referenced in the webcast, click here.